<DOC>
	<DOC>NCT00080262</DOC>
	<brief_summary>The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.</brief_summary>
	<brief_title>Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients must have received all 3 drugs an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant No more than 3 prior chemotherapy regimens in the metastatic setting Must have at least one target lesion that is radiographically measurable Good performance status No history of or current brain or leptomeningeal disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>